Review: taking Januvia and Victoza together


Summary

Drug interactions are reported among people who take Januvia and Victoza together. This review analyzes the effectiveness and drug interactions between Januvia and Victoza. It is created by eHealthMe based on reports of 327 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Januvia and Victoza >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Januvia

Januvia has active ingredients of sitagliptin phosphate. It is often used in diabetes. (latest outcomes from Januvia 25,365 users)

Victoza

Victoza has active ingredients of liraglutide. It is often used in type 2 diabetes. (latest outcomes from Victoza 15,243 users)

On Aug, 26, 2016

327 people who take Januvia, Victoza are studied.


Number of reports submitted per year:

Januvia and Victoza drug interactions.

Drug effectiveness over time:

Januvia:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Victoza:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Januvia:
  • female: 0.0% - (0 of 1 people)
  • male: 33.0% - (1 of 3 people)
Victoza:
  • female: 0.0% - (0 of 1 people)
  • male: 33.0% - (1 of 3 people)

Drug effectiveness by age:

Januvia:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 50.0% - (1 of 2 people)
  • 60+: 0.0% - (0 of 2 people)
Victoza:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 50.0% - (1 of 2 people)
  • 60+: 0.0% - (0 of 2 people)

Most common drug interactions over time *:

< 1 month:
  • nausea
  • pancreatitis
  • pancreatitis acute
  • vomiting
  • diarrhoea
  • abdominal pain
  • ileus
  • pyrexia
  • asthenia
  • constipation
1 - 6 months:
  • pancreatitis
  • pancreatitis acute
  • blood glucose increased
  • nausea
  • pancreatic carcinoma
  • acute abdomen
  • constipation
  • glycosylated haemoglobin increased
  • weight decreased
  • decreased appetite
6 - 12 months:
  • pancreatic carcinoma
  • pancreatitis
  • asthenia
  • constipation
  • hyperhidrosis
  • thyroid cancer
  • diplopia
  • myasthenia gravis
  • nephropathy toxic
  • neuropathy peripheral
1 - 2 years:
  • blood glucose increased
  • pancreatic carcinoma
  • drug ineffective
  • glycosylated haemoglobin increased
  • pleural mesothelioma
  • abdominal pain
  • hepatic failure
  • hypertension
  • pancreatitis
  • adverse event
2 - 5 years:
  • pancreatic carcinoma
  • acute abdomen
  • pancreatic carcinoma metastatic
  • pancreatitis
  • atrial fibrillation
  • adenocarcinoma pancreas
  • back pain
  • death
  • gastrooesophageal reflux disease
  • hypertension
5 - 10 years:
  • cholangiocarcinoma
  • metastases to liver
  • adenocarcinoma pancreas
  • itching
  • pancreatic carcinoma
  • acute respiratory failure
  • anaemia of chronic disease
  • atrial fibrillation
  • bipolar disorder
  • chronic obstructive pulmonary disease
not specified:
  • blood glucose increased
  • nausea
  • pancreatitis
  • diarrhoea
  • weight decreased
  • pancreatic carcinoma
  • headache
  • pancreatitis acute
  • abdominal pain
  • alanine aminotransferase increased

Most common drug interactions by gender *:

female:
  • pancreatic carcinoma
  • nausea
  • pancreatitis
  • diarrhoea
  • blood glucose increased
  • headache
  • constipation
  • flatulence
  • pancreatitis acute
  • weight decreased
male:
  • blood glucose increased
  • nausea
  • pancreatitis
  • pancreatic carcinoma
  • pancreatitis acute
  • abdominal pain
  • weight decreased
  • glycosylated haemoglobin increased
  • diarrhoea
  • alanine aminotransferase increased

Most common drug interactions by age *:

20-29:
  • colon cancer stage iii
  • rectal haemorrhage
  • angioedema
  • constipation
  • decreased appetite
  • dizziness
  • loss of consciousness
  • rash erythematous
  • weight decreased
30-39:
  • pancreatitis acute
  • blood glucose increased
  • abdominal pain
  • musculoskeletal pain
  • overdose
  • pain
  • skin lesion
40-49:
  • pancreatitis
  • blood glucose increased
  • nausea
  • pancreatitis acute
  • glycosylated haemoglobin increased
  • ileus
  • diarrhoea
  • flatulence
  • vomiting
  • abdominal discomfort
50-59:
  • pancreatitis
  • blood glucose increased
  • nausea
  • diarrhoea
  • pancreatic carcinoma
  • vision blurred
  • drug ineffective
  • acute abdomen
  • death
  • hepatic failure
60+:
  • nausea
  • blood glucose increased
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • blood alkaline phosphatase increased
  • headache
  • hyperbilirubinaemia
  • pancreatitis
  • weight decreased
  • abdominal pain

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Januvia and Victoza?

Can you answer these questions?

More questions for: Januvia, Victoza

You may be interested in these reviews

More reviews for: Januvia, Victoza

On eHealthMe, Januvia (sitagliptin phosphate) is often used to treat diabetes. Victoza (liraglutide) is often used to treat type 2 diabetes. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.